MedTrace Logo

A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

NCT07391761 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-05-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate:

* What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan?
* What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan?
* What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?

Conditions

  • Refractory Multiple Myeloma (RRMM)

Interventions

DRUG

Non intervention

Non intervention

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2028-01-31
Completion
2028-01-31
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07391761 on ClinicalTrials.gov